The Robert M. Berne Cardiovascular Research Center
Presents

Paul Gurbel, PhD

Professor of Medicine, Division of Cardiology, Johns Hopkins University ~ Adjunct Professor of Medicine, Division of Cardiology, Duke University ~ Doctor Honoris Causa, Nicolaus Copernicus University, Poland ~ Director, Interventional Cardiology and Cardiovascular Medicine Research, Inova Health ~ Director, Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute

Drug Development at Inova Heart and Vascular Institute: First Human Administration of a Pepducin

Pepducins are lipitated peptides, which specifically target the cytoplasmic surface of their cognate receptor and can act as either allosteric agonists or antagonists. PZ-128 is a cell-penetrating lipopeptide pepducin that selectively inhibits PAR1-G protein signaling on the inner leaflet of the lipid bilayer. It is a promising antiplatelet agent with rapid, specific, dose dependent, and reversible inhibition of platelet protease-activated receptor-1 through a novel intracellular mechanism. It is being developed for prevention of acute thrombotic complications of PCI.

Thursday September 7, 2017
11:00 AM – 12:00 PM
MR5 3005

Refreshments Served
Hosted by: Weibin Shi